The UK and US have secured a major trade agreement that will preserve no tariffs on UK medicine products going into the US market.
The Terms of the Deal
As part of the deal, the UK has pledged to boost spending on drugs through the NHS. This commitment secures that tariffs on these vital goods will remain at zero for a period of 36 months.
This development comes after previous threats to significantly raise tariffs on branded pharmaceutical imports, with potential rates discussed up to 100%.
"This deal between the UK strengthens the international landscape for cutting-edge drugs and brings much-needed balance to transatlantic medicine commerce," a release said.
Commercial Impact
Medicines constitute one of the the United Kingdom's most significant export categories to the America, which is by far the biggest market for major companies like GSK and AstraZeneca.
Trade data reveal that in the 12 months prior to last September, the UK shipped pharmaceutical products totaling over eleven billion pounds to the US. This value represented 17.4% of all goods exports in that span.
"This deal protects employment, increases capital expenditure and sets the stage for the UK to establish itself as a international leader for medical research," the Business and Trade Secretary commented.
Specific UK Commitments
The agreement includes several key commitments from the UK:
- Higher Cost Ceiling: The UK will increase the cost ceiling at which it considers new medicines to be prohibitively costly by 25%.
- Higher Drug Budget: There is a aim to raise total public funding on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the coming ten years.
- Refund Ceiling: The sum pharmaceutical firms must return to the NHS to control costs will be limited at 15%. Last year, rebates were more than 20%.
Industry Background
The pact follows a protracted row between the sector and the ministers over medicine costs and NHS adoption.
These tensions were intensified by assertions that American customers were paying several times more for the identical medicines than consumers in the UK and Europe.
Recently, several large pharmaceutical investments in the UK have been paused or abandoned, while multi-billion-dollar investments have been announced toward American operations.
A senior figure publicly accepted that the NHS had to invest a greater share on medicines, noting that its expenditure on drugs had shrunk as a percentage of its total funding over the past decade.
